Publications

UNAIDS and the World Health Organization have published this updated guidance on ethical considerations in HIV prevention trials. The new guidance is the result of a year-long process that saw more than 80 experts and members of the public give inputs and is published 21 years after the first edition appeared.

Globally, at the end of 2017, only 5 million – or 7% – of the 71 (62–79) million people chronically infected with HCV had cumulatively received treatment with DAAs. As countries continue to tackle the disease burden and service disruptions caused by the COVID-19 pandemic, it is critical to ensure that the recent momentum and gains in the response to hepatitis C are not lost. Against this backdrop, this report is a strong reminder to continue to invest in building resilient and sustainable health systems that are focused on universal health coverage.

MAC’s Human Rights Initiative aims to facilitate effective linkages to care and support for HIV-infected and affected individuals; and to protect them from the harmful impact of stigma and discrimination. Despite the effectiveness of HIV treatment and HIV being a manageable chronic illness, individuals living with HIV continue experiencing human rights violations in many circumstances, including in the education sector and workplace. MAC aims to end this vicious cycle by vigorously engaging with the relevant stakeholders in order to heighten the awareness about the issue.

The checklist and reference list is meant to complement and build on the most recent normative guidelines produced by UNAIDS Cosponsors and the Secretariat and not to replace them. The checklist has built-in hyperlinks for such guidelines for easy reference. The checklist and reference list has two parts: high-level cross-cutting content (Part A) and specific programme content (Part B). 

The purpose of this document is to provide guidance to national AIDS programmes and partners on the use of indicators to measure and report on the country HIV response.

The COVID-19 vaccines under development or approved by regulators are believed to be safe for most people, including people living with HIV. 

This report provides a summary of key developments in the legal environment for HIV responses in Asia and the Pacific. It is the product of a desk review conducted for UNAIDS and the United Nations Development Programme (UNDP) in 2019. The report highlights key trends and developments in laws affecting people living with HIV and key populations in Asia and the Pacific over the five-year period 2014–2019.

The current HIV program is reaching KPs and PLHIV for prevention and treatment of HIV. The integrated intervention to KPs and providing HCV related activities like prevention, early diagnosis and providing treatment to cure HCV infection would be the cost-effective approach to decrease the burden of HCV among them. The availability of effective treatment – Direct - Acting Antiviral (DAA) has prevented HCV related consequences and cured from HCV infections. The pangenotypic DAA do not require genotyping of the virus and current WHO guidelines recommends that all HCV infected people are treated with minimal lab investigations and follow up. This recommendation helps us to combat Hep C related complications and prevent morbidities and mortalities and provide opportunity to treat clients at all kind of health facilities.

People who use drugs, especially people who smoke or inject drugs, face additional risks and vulnerabilities to COVID-19 infection compared to the general population. Maintaining services for this population and safeguarding funding for harm reduction is therefore crucial. The pandemic and related responses have affected harm reduction service provision and the lives of people who use drugs worldwide. Understanding the impact of COVID-19 on harm reduction funding and service provision is essential for informing donor and government action as well as civil society advocacy. This report and briefing summarise evidence from civil society in seven Asian countries (Cambodia, India, Indonesia, Nepal, Thailand, the Philippines and Vietnam) and provides recommendations to donors and governments on protecting harm reduction in the COVID-19 era.  

The 2018-2019 Annual Report highlights progress made around the Asia Pacific Region to make the vision of the United Nations Sustainable Development Goals a reality for women and girls. UN Women stands behind women’s equal participation in all aspects of life, focusing on five priority areas: increasing women’s leadership and participation; ending violence against women; engaging women in all aspects of peace and security processes; enhancing women's economic empowerment. The report emphasizes these programming achievements which are made possible from collaboration and cooperation with valued partners and donors all teaming up for gender equality.